| Resistance pattern | Name of the drugs | Total patients N = 102 n (%) | New patients N = 38 n (%) | Previously treated patients N = 64 n (%) | P value* |
| Susceptible to all four drugs | SM + INH + RIF + EMB | 63 (61.8) | 27 (71.1) | 36 (56.2) | 0.137 |
| Mono drug resistance |
| 18 (17.6) | 6 (15.8) | 12 (18.7) | 0.730 |
|
| SM INH RIF EMB | 3 (2.9) 11 (10.8) 2 (1.9) 2 (1.9) | 1 (2.6) 4 (10.5) 0 (0.0) 1 (2.6) | 2 (3.1) 7 (10.9) 2 (3.1) 1 (1.6) | 0.887 0.271 0.948 0.707 |
| Double drug resistance |
| 14 (13.7) | 3 (7.9) | 11 (17.2) | 0.433 |
|
| INH + RIF | 8 (7.8) | 1 (2.6) | 7 (10.9) | 0.131 |
|
| RIF + SM | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
|
| SM + EMB | 1 (1) | 0 (0.0) | 1 (1.6) | 0.439 |
|
| EMB + INH | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
|
| RIF + EMB | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
|
| SM + INH | 5 (4.9) | 2 (5.3) | 3 (4.7) | 0.896 |
| Triple drug resistance |
| 4 (3.9) | 2 (5.3) | 2 (3.1) | 0.248 |
|
| INH + RIF + SM | 3 (2.9) | 1 (2.6) | 2 (3.1) | 0.887 |
|
| SM + EMB + INH | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
|
| INH + RIF + EMB | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
|
| RIF + EMB + SM | 1 (1) | 1 (2.7) | 0 (0.0) | 0.192 |
| Quadruple drug resistance | SM + INH + RIF + EMB | 1 (1) | 0 (0.0) | 1 (1.6) | 0.386 |
| MDR-TB | At least INH + RIF | 12 (11.7) | 2 (5.3) | 10 (15.6) | 0.116 |